Radiopharm Theranostics

Corporate Governance

ASX Announcements

Updates

Home

Manrope

Click here to visit our dedicated Entitlement Offer (NREO) page for all the information you need to participate. 

Radiopharm Theranostics (ASX:RAD) is dedicated to developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications, addressing high unmet medical needs. 

In 2024, the company made significant strides in its cancer research. 

In this interview with Kalkine Media, the company’s Managing Director and CEO Mr. Riccardo Canevari shares insights into the key milestones achieved over the past year, including progress in clinical trials, strategic partnerships, and the company’s key priorities and plans for 2025.

Cancer Research Milestones and 2025 Roadmap